Provectus Biopharma Files Proxy Statement

TL;DR

PROVECTUS BIOPHARMACEUTICALS FILED A PROXY STATEMENT, NO FEE REQUIRED.

AI Summary

Provectus Biopharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 20, 2024. The filing indicates no fee was required for this submission. The company is incorporated in Delaware and its fiscal year ends on December 31st.

Why It Matters

This filing is a routine proxy statement, providing shareholders with information regarding company matters, typically for upcoming shareholder meetings.

Risk Assessment

Risk Level: low — This is a standard regulatory filing (DEFA14A) with no immediate indication of significant financial or operational changes.

Key Players & Entities

• PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Registrant
• 0001493152-24-024379 (filing_id) — Accession Number
• 20240620 (date) — Filing Date
• DEFA14A (document_type) — Form Type

FAQ

Filing Documents

• formdefa14a.htm (DEFA14A) — 33KB
• formdefa14a_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-024379.txt ( ) — 39KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 Provectus Biopharmaceuticals, Inc. (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check the appropriate box): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11 Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and a company update, will be accessible by Zoom Webinar. The meeting will be held on Thursday, June 20, 2024 at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time. The 2024 Annual Meeting webinar may be accessed by registering in advance here: https://us06web.zoom.us/webinar/register/WN_KZTlQulrRCOZ2qQI4C23mQ#/registration . The webinar is being made available only for informational purposes. The 2024 Annual Meeting is being held in person, and accessing the webinar will neither count as attendance for purposes of meeting quorum requirements nor enable a stockholder to vote. Provectus’s stockholders of record at the close of business on April 24, 2024, the record date for the 2024 Annual Meeting, may vote at the meeting by attending in person or following the instructions in the Company’s proxy materials. Availability of Proxy Materials In connection with the 2024 Annual Meeting, Provectus has filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) on May 6, 2024, which may be found here: https://www.sec.gov/Archives/edgar/data/315545/000149315224017882/formdef14a.htm . The Company mailed a Notice of Internet Availability of Proxy Materials (“Notice”) to its stockholders on or about May 10, 2024. These materials, along with Provectus’s 2023 Annual Report, are available on the Company’s website and may be found here: https://www.provectusbio.com/annual-meeting/ . About Provectus Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic bioactive small molecules called halogenated xanthenes. The Company’s lead HX molecule is named Rose Bengal Sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov . For additional information about Provectus, please visit the Company’s website at www.provectusbio.com . Forward Looking Statements The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or The safety and efficacy of the agents and/or uses under investigation ha

View Full Filing

View this DEFA14A filing on SEC EDGAR